Machine learning reveals key markers for healthy aging, separate from chronic disease risks

Every year, with­out fail, the End­points 11 proves to be the most chal­leng­ing project I face — and def­i­nite­ly re­mains the most fun. In an

The FDA granted accelerated approval to afamitresgene autoleucel (afami-cel, Tecelra) for treating advanced synovial sarcoma, the first engineered cell therapy indicated for a solid tumor.

Ex­elix­is is lay­ing off 175 em­ploy­ees, or 13% of its work­force, to “re­bal­ance re­sources” with a fo­cus on can­di­dates clos­er to mar­ket. The com­pa­ny ap­pears